Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-06-14, Stock:NVS, The news for the past five days is as follows:
2019-06-07: NEWS1: Celgene's Filing for Ozanimod Accepted for Review in US/EU.NEWS2: Celgene's Filing for Ozanimod Accepted for Review in US/EU.NEWS3: Celgene's Filing for Ozanimod Accepted for Review in US/EU.NEWS4: New Sanofi CEO 2019: 8 Things to Know About Paul Hudson.NEWS5: New Sanofi CEO 2019: 8 Things to Know About Paul Hudson.NEWS6: Sanofi's Leadership Transition: What You Need To Know.NEWS7: New Sanofi CEO 2019: 8 Things to Know About Paul Hudson.NEWS8: Here’s What Hedge Funds Think About Novartis AG  (NVS).NEWS9: Sanofi Taps Novartis Executive as CEO in Race for New Drugs.NEWS10: Novartis Appoints New Pharma Unit Head, Gives Other Updates.NEWS11: Novartis Appoints New Pharma Unit Head, Gives Other Updates.NEWS12: Novartis Appoints New Pharma Unit Head, Gives Other Updates.NEWS13: The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix.NEWS14: Sanofi appoints top Novartis executive as new chief.NEWS15: Sanofi says Paul Hudson to succeed Olivier Brandicourt as chief.NEWS16: StockBeat: Markets Rise as Miserable German Data Boost QE Hopes.
2019-06-10: NEWS1: Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug.NEWS2: Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug.NEWS3: Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug.NEWS4: Roche Receives FTC Request for Further Data on Spark Buyout.NEWS5: Roche Receives FTC Request for Further Data on Spark Buyout.NEWS6: Curium Bidco S.a.r.l -- Moody's assigns B2 CFR to Curium Bidco S.a.r.l.; outlook stable.NEWS7: Roche Receives FTC Request for Further Data on Spark Buyout.
2019-06-11: NEWS1: Stoke Therapeutics boosts IPO goal by 40 percent.
2019-06-12: NEWS1: Roche's Rituxan Gets Priority Review for Blood Disorder.NEWS2: Novartis Reports Data on Cosentyx for Psoriatic Arthritis.
2019-06-13: NEWS1: Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris.NEWS2: Top Analyst Reports for Visa, Netflix & Accenture.NEWS3: Top Analyst Reports for Visa, Netflix & Accenture.NEWS4: Top Analyst Reports for Visa, Netflix & Accenture.NEWS5: Ligand Inks Oncology Drug Discovery Deal With PhoreMost.NEWS6: Ligand Inks Oncology Drug Discovery Deal With PhoreMost.NEWS7: Ligand Inks Oncology Drug Discovery Deal With PhoreMost.NEWS8: A Stock Fund Challenges the Definition of Growth. It’s Paying Off..NEWS9: Novartis Reports Data on Cosentyx for Psoriatic Arthritis.NEWS10: Novartis Reports Data on Cosentyx for Psoriatic Arthritis.NEWS11: Roche's Rituxan Gets Priority Review for Blood Disorder.NEWS12: Roche's Rituxan Gets Priority Review for Blood Disorder.

Answer: Decrease